Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IJ7H
|
|||
| Former ID |
DNC002676
|
|||
| Drug Name |
3-Hydroxy-3-Methyl-Glutaric Acid
|
|||
| Synonyms |
Meglutol; MEGLUTOL; 3-Hydroxy-3-methylglutaric acid; 503-49-1; Dicrotalic acid; 3-Hydroxy-3-methylpentanedioic acid; Lipoglutaren; Medroglutaric acid; 3-hydroxy-3-methyl-glutaric acid; HMGA; beta-Hydroxy-beta-methylglutaric acid; Meglutolum; Meglutol [USAN:INN]; Meglutolum [INN-Latin]; Pentanedioic acid, 3-hydroxy-3-methyl-; CB-337; CB 337; UNII-CLA99KCD53; 3-Hydroxy-3-methylglutarate; Glutaric acid, 3-hydroxy-3-methyl-; EINECS 207-971-1; NSC 361411; 3-Hydroxymethylglutaric acid; BRN 1769194; CLA99KCD53; CHEMBL50444; CHEBI:16831
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H10O5
|
|||
| Canonical SMILES |
CC(CC(=O)O)(CC(=O)O)O
|
|||
| InChI |
1S/C6H10O5/c1-6(11,2-4(7)8)3-5(9)10/h11H,2-3H2,1H3,(H,7,8)(H,9,10)
|
|||
| InChIKey |
NPOAOTPXWNWTSH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 503-49-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6518, 465638, 837449, 837453, 3138613, 4360728, 7888751, 8145751, 8151224, 12015709, 15147019, 24895642, 29220866, 46508063, 47193667, 47206661, 48334702, 48334703, 49973038, 50113539, 57320970, 57654253, 74614918, 85165135, 87570836, 88531321, 92298537, 103232312, 104047199, 104298356, 104829164, 118693189, 121362113, 125482710, 126523199, 126558056, 128736160, 134342184, 134975893, 135366238, 137006331, 139145840, 144027053, 144076405, 160798467, 160967404, 162265616, 163086679, 164188133, 164810982
|
|||
| ChEBI ID |
CHEBI:16831
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HMG-CoA reductase (HMGCR) | Target Info | Inhibitor | [1], [2] |
| BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
| Superpathway of cholesterol biosynthesis | ||||
| Mevalonate pathway | ||||
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| AMPK signaling pathway | ||||
| Bile secretion | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| TSH Signaling Pathway | ||||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| WikiPathways | Statin Pathway | |||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
| Activation of Gene Expression by SREBP (SREBF) | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Integrated Breast Cancer Pathway | ||||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
| REF 2 | Molecular docking of the highly hypolipidemic agent alpha-asarone with the catalytic portion of HMG-CoA reductase. Bioorg Med Chem Lett. 2005 Feb 15;15(4):989-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.